DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Exploring the Roles of Biomolecular Condensates (BMCs) in HIV replication, latency, or pathogenesis in the context of substance use disorders (R21/R33 Clinical Trial Not Allowed)

Date: September 22, 2020

Time: 10:00 AM to 11:30 AM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health
3 White Flint North, 9th Floor
301 North Stonestreet Avenue
Bethesda, MD 20892
(Virtual Meeting)

Contact Person: Trinh T. Tran, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
Division of Extramural Research
National Institute on Drug Abuse, NIH
3WFN 9th Floor, MSC 6021
301 North Stonestreet Avenue
Bethesda, MD 20892
(301) 827-5843
trinh.tran@nih.gov
Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01 and R34)

Date: September 25, 2020

Time: 12:00 PM to 3:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health
3 White Flint North, 9th Floor
301 North Stonestreet Avenue
Bethesda, MD 20892
(Virtual Meeting)

Contact Person: Yvonne Owens Ferguson, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
Division of Extramural Research
National Institute on Drug Abuse, NIH
3WFN 9th Floor, MSC 6021
301 North Stonestreet Avenue
Bethesda, MD 20892
(301) 402-7371
yvonne.ferguson@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Exploiting Genome or Epigenome Editing to Functionally Validate Genes or Variants Involved in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)

Date: October 15, 2020

Time: 1:30 PM to 4:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health
3 White Flint North, 9th Floor
301 North Stonestreet Avenue
Bethesda, MD 20892
(Virtual Meeting)
Contact Person: Ipolia R. Ramadan, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
Division of Extramural Research
National Institute on Drug Abuse, NIH
3WFN 9th Floor, MSC 6021
301 North Stonestreet Avenue
Bethesda, MD 20892
(301) 827-4471
ramadanir@mail.nih.gov


Dated: ____________________ August 26, 2020.________________

Tyeshia M. Roberson, Program Analyst,
Office of Federal Advisory Committee Policy.
[FR Doc. 2020-19220 Filed: 8/31/2020 8:45 am; Publication Date: 9/1/2020]